These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1400 related items for PubMed ID: 33113414

  • 1. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
    El-Adl K, El-Helby AA, Sakr H, Elwan A.
    Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
    [Abstract] [Full Text] [Related]

  • 2. Design and Discovery of Novel Quinoxaline Derivatives as Dual DNA Intercalators and Topoisomerase II Inhibitors.
    Eissa IH, El-Naggar AM, El-Sattar NEAA, Youssef ASA.
    Anticancer Agents Med Chem; 2018 Dec; 18(2):195-209. PubMed ID: 28699490
    [Abstract] [Full Text] [Related]

  • 3. Discovery of novel triazolophthalazine derivatives as DNA intercalators and topoisomerase II inhibitors.
    Sakr H, Ayyad RR, El-Helby AA, Khalifa MM, Mahdy HA.
    Arch Pharm (Weinheim); 2021 Jun; 354(6):e2000456. PubMed ID: 33554352
    [Abstract] [Full Text] [Related]

  • 4. Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative Topo II inhibitors and apoptosis inducers.
    Abbass EM, Khalil AK, Mohamed MM, Eissa IH, El-Naggar AM.
    Bioorg Chem; 2020 Nov; 104():104255. PubMed ID: 32927130
    [Abstract] [Full Text] [Related]

  • 5. Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors.
    Ibrahim MK, Taghour MS, Metwaly AM, Belal A, Mehany ABM, Elhendawy MA, Radwan MM, Yassin AM, El-Deeb NM, Hafez EE, ElSohly MA, Eissa IH.
    Eur J Med Chem; 2018 Jul 15; 155():117-134. PubMed ID: 29885574
    [Abstract] [Full Text] [Related]

  • 6. Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors.
    Eissa IH, Metwaly AM, Belal A, Mehany ABM, Ayyad RR, El-Adl K, Mahdy HA, Taghour MS, El-Gamal KMA, El-Sawah ME, Elmetwally SA, Elhendawy MA, Radwan MM, ElSohly MA.
    Arch Pharm (Weinheim); 2019 Nov 15; 352(11):e1900123. PubMed ID: 31463953
    [Abstract] [Full Text] [Related]

  • 7. Design and discovery of new 1,2,4-triazolo[4,3-c]quinazolines as potential DNA intercalators and topoisomerase II inhibitors.
    Alesawy MS, Al-Karmalawy AA, Elkaeed EB, Alswah M, Belal A, Taghour MS, Eissa IH.
    Arch Pharm (Weinheim); 2021 Mar 15; 354(3):e2000237. PubMed ID: 33226150
    [Abstract] [Full Text] [Related]

  • 8. [1,2,4]Triazolo[4,3-c]quinazoline and bis([1,2,4]triazolo)[4,3-a:4',3'-c]quinazoline derived DNA intercalators: Design, synthesis, in silico ADMET profile, molecular docking and anti-proliferative evaluation studies.
    El-Adl K, Ibrahim MK, Alesawy MSI, Eissa IH.
    Bioorg Med Chem; 2021 Jan 15; 30():115958. PubMed ID: 33360576
    [Abstract] [Full Text] [Related]

  • 9. Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and in vivo studies.
    Khalifa MM, Al-Karmalawy AA, Elkaeed EB, Nafie MS, Tantawy MA, Eissa IH, Mahdy HA.
    J Enzyme Inhib Med Chem; 2022 Dec 15; 37(1):299-314. PubMed ID: 34894955
    [Abstract] [Full Text] [Related]

  • 10. Pharmacophore-based, rationale design, and efficient synthesis of novel tetrahydrobenzo[b]thiophene candidates as potential dual Topo I/II inhibitors and DNA intercalators.
    Nofal HR, Al-Karmalawy AA, Elmaaty AA, Ismail MF, Ali AK, Abbass EM.
    Arch Pharm (Weinheim); 2024 Sep 15; 357(9):e2400217. PubMed ID: 38864845
    [Abstract] [Full Text] [Related]

  • 11. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA, Sakr H, Ayyad RRA, El-Adl K, Ali MM, Khedr F.
    Anticancer Agents Med Chem; 2018 Sep 15; 18(8):1184-1196. PubMed ID: 29651967
    [Abstract] [Full Text] [Related]

  • 12. Triazoloquinoxalines-based DNA intercalators-Topo II inhibitors: design, synthesis, docking, ADMET and anti-proliferative evaluations.
    Elwan A, Sakr H, El-Helby AA, El-Morsy A, Abdelgawad MA, Ghoneim MM, El-Sherbiny M, El-Adl K.
    J Enzyme Inhib Med Chem; 2022 Dec 15; 37(1):1556-1567. PubMed ID: 35635148
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis, molecular modeling, in vivo studies and anticancer activity evaluation of new phthalazine derivatives as potential DNA intercalators and topoisomerase II inhibitors.
    El-Helby AA, Sakr H, Ayyad RR, Mahdy HA, Khalifa MM, Belal A, Rashed M, El-Sharkawy A, Metwaly AM, Elhendawy MA, Radwan MM, ElSohly MA, Eissa IH.
    Bioorg Chem; 2020 Oct 15; 103():104233. PubMed ID: 32882440
    [Abstract] [Full Text] [Related]

  • 14. Novel quinazolin-2-yl 1,2,3-triazole hybrids as promising multi-target anticancer agents: Design, synthesis, and molecular docking study.
    El Hamaky NFM, Hamdi A, Bayoumi WA, Elgazar AA, Nasr MNA.
    Bioorg Chem; 2024 Jul 15; 148():107437. PubMed ID: 38749114
    [Abstract] [Full Text] [Related]

  • 15. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation.
    Alanazi MM, Mahdy HA, Alsaif NA, Obaidullah AJ, Alkahtani HM, Al-Mehizia AA, Alsubaie SM, Dahab MA, Eissa IH.
    Bioorg Chem; 2021 Jul 15; 112():104949. PubMed ID: 34023640
    [Abstract] [Full Text] [Related]

  • 16. 4β-amidotriazole linked podophyllotoxin congeners: DNA topoisomerase-IIα inhibition and potential anticancer agents for prostate cancer.
    Reddy VG, Bonam SR, Reddy TS, Akunuri R, Naidu VGM, Nayak VL, Bhargava SK, Kumar HMS, Srihari P, Kamal A.
    Eur J Med Chem; 2018 Jan 20; 144():595-611. PubMed ID: 29289884
    [Abstract] [Full Text] [Related]

  • 17. Antiproliferative evaluations of triazoloquinazolines as classical DNA intercalators: Design, synthesis, ADMET profile, and molecular docking.
    Eissa IH, Ibrahim MK, Alesawy MS, El-Adl K.
    Arch Pharm (Weinheim); 2022 May 20; 355(5):e2100487. PubMed ID: 35194810
    [Abstract] [Full Text] [Related]

  • 18. Design, synthesis, in silico ADMET, docking, and antiproliferative evaluations of [1,2,4]triazolo[4,3-c]quinazolines as classical DNA intercalators.
    Alesawy MS, Ibrahim MK, Eissa IH, El-Adl K.
    Arch Pharm (Weinheim); 2022 Apr 20; 355(4):e2100412. PubMed ID: 35014084
    [Abstract] [Full Text] [Related]

  • 19. Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies.
    Alsaif NA, Taghour MS, Alanazi MM, Obaidullah AJ, Alanazi WA, Alasmari A, Albassam H, Dahab MA, Mahdy HA.
    Bioorg Med Chem; 2021 Sep 15; 46():116384. PubMed ID: 34479065
    [Abstract] [Full Text] [Related]

  • 20. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
    El-Adl K, El-Helby AA, Sakr H, Ayyad RR, Mahdy HA, Nasser M, Abulkhair HS, El-Hddad SSA.
    Arch Pharm (Weinheim); 2021 Feb 15; 354(2):e2000279. PubMed ID: 33073374
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 70.